Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25042615 | 0.88 | BCL9 (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL13629555 | 0.86 | BCL9 (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL14962749 | 0.85 | BCL9 (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL29277468 | 0.84 | MGLL (0.57) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL4683792 | 0.83 | GAA (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL60448 | 0.83 | MGLL (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL7073161 | 0.83 | MGLL (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL28063044 | 0.83 | MGLL (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL7075032 | 0.83 | MGLL (0.60) | BCL9CTNNB1HTR2AGAAMGLL | |
| SCHEMBL7787944 | 0.83 | BCL9 (0.57) | BCL9CTNNB1HTR2AGAAMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2023-02-16 | — | — | US | disclosed |
| EP-2264157-B1 | Lipolytic enzyme variants | NOVOZYMES AS (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2264159-B1 | Lipolytic enzyme variants | NOVOZYMES AS (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2099908-B1 | LIPOLYTIC ENZYME VARIANTS | NOVOZYMES AS (DK) | 2014-05-14 | — | — | EP | disclosed |
| EP-2267121-B1 | Lipolytic enzyme variants | NOVOZYMES AS (DK) | 2014-05-14 | — | — | EP | disclosed |
| US-20130157325-A1 | Lipolytic Enzyme Variants | NOVOZYMES A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| US-20130157325-A1 | Lipolytic Enzyme Variants | NOVOZYMES A/S (DK) | 2013-06-20 | — | — | US | disclosed |
| CN-102648178-A | Quinazoline derivatives | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| EP-2444501-A1 | Sensor | Université de Fribourg (CH) | 2012-04-25 | — | — | EP | disclosed |
| CN-102076650-A | Carboxylic acid compound | DAIICHI SANKYO CO LTD | 2011-05-25 | — | — | CN | disclosed |
| EP-2267121-A2 | Lipolytic enzyme variants | Novozymes A/S (DK) | 2010-12-29 | — | — | EP | disclosed |
| EP-2264158-A2 | Lipolytic enzyme variants | Novozymes A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264157-A2 | Lipolytic enzyme variants | Novozymes A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| EP-2264159-A2 | Lipolytic enzyme variants | Novozymes A/S (DK) | 2010-12-22 | — | — | EP | disclosed |
| US-20100047836-A1 | LIPOLYTIC ENZYME VARIANTS | NOVOZYMES A/S (DK) | 2010-02-25 | — | — | US | disclosed |
| US-20100047836-A1 | LIPOLYTIC ENZYME VARIANTS | NOVOZYMES A/S (DK) | 2010-02-25 | — | — | US | disclosed |
| WO-2008065060-A2 | LIPOLYTIC ENZYME VARIANTS | NOVOZYMES A/S (DK) | 2008-06-05 | — | — | WO | disclosed |
| US-20080076137-A1 | Bioanalytic Systems and Methods | CELLEXICON, INC. | 2008-03-27 | — | — | US | disclosed |
| CN-1589258-A | Novel beta -phenyl- alpha -oxysubstituted propionic derivatives: process for their preparation and their use in the preparation of pharmaceutically important compounds | REDDY S LAB LTD (IN) | 2005-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076137-A1 | Bioanalytic Systems and Methods | GUSB, ENGASE, FUCA2 | BCL9 1155/4885CTNNB1 2868/4885HTR2A 4264/4885 |
| US-20230052140-A1 | IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF | IGF1R, IGFBP1, IGFBP2 | BCL9 902/4885CTNNB1 4596/4885HTR2A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.